Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 69

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 69
---
 have not been prepared as pro forma
results under applicable regulations, may not reflect the actual results we would have achieved had the Business Combination occurred
at the beginning of fiscal 2024, and should not be viewed as a substitute for the results of operations of the Predecessor and Successor
periods presented in accordance with U.S. GAAP.

<div align='center'>40</div>

Comparison of the period commencing July 24, 2024 through December 31, 2024 (Successor and Predecessor) to the period commencing July 24, 2024 through December 31, 2024 (Predecessor)

The following table is data derived from the
Consolidated Statement of Operations (in thousands) and the discussions that follow are in approximate amounts.

|                                     |     | Successor and Predecessor |       |   |     |         Predecessor |     |
|                                     |     |                   For the 
                    period 
        commencing July 24 |       |   |     |             For the 
              period 
  commencing July 24 |     |
|                                     |     |       through December 31 |       |   |     | through December 31 |     |
|                                     |     |                      2024 |       |   |     |                2024 |     |
|                                     |     |                 Unaudited |       |   |     |           Unaudited |     |
| Operating expenses                  |     |                           |       |   |     |                     |     |
| Research and development expenses   |     |                           |   996 |   |     |                     | 670 |
| General and administrative expenses |     |                           | 1,153 |   |     |                     | 103 |
| Operating loss                      |     |                           | 2,149 |   |     |                     | 773 |
| Financial expense (income), net     |     |                           |   (65 | ) |     |                     |  10 |
| Net loss and comprehensive loss     |     |                           | 2,084 |   |     |                     | 783 |

Research and Development Expenses

Successor’s and Predecessor’s research
and development expenses totaled $996 thousand for the period commencing July 24, 2024 through December 31, 2024, representing an increase
of $326 thousand, or 48.6%, compared to Predecessor’s $670 thousand for the